

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/011767 A1

(51) International Patent Classification⁷: **A61L 27/34**,
27/18, 29/08, 29/06, 31/06, 31/10

(21) International Application Number:
PCT/US2004/024586

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/632,008 31 July 2003 (31.07.2003) US

(71) Applicant (for all designated States except US): **SCIMED
LIFE SYSTEMS, INC.** [US/US]; One Scimed Place,
Maple Grove, MN 55311-1566 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RICHARD, Robert**,
E. [US/US]; 2570 West St., Wrentham, MA 02093 (US).
SCHWARZ, Marlene, C. [US/US]; 161 Islington Road,
Auburndale, MA 02446 (US). **STRICKLER, Frederick**,
H. [US/US]; 45 Village Brook Lane #5, Natick, MA 01760
(US).

(74) Agents: **BONHAM, David, B.** et al.; Mayer Forkort &
Williams, P.C., 251 North Avenue West, 2nd Floor, West-
field, NJ 07090 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ; OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **IMPLANTABLE OR INSERTABLE MEDICAL DEVICES CONTAINING SILICONE COPOLYMER FOR CON-
TROLLED DELIVERY OF THERAPEUTIC AGENTS**

(57) Abstract: Implantable or insertable medical devices are described. The medical devices comprise (a) a therapeutic agent and
(b) a polymeric release region, which controls the release of the therapeutic agent upon administration to a patient. The polymeric
release region further comprises a silicone copolymer that contains a plurality of siloxane units and a plurality of non-siloxane units.
Also described are methods for administering a therapeutic agent to a patient using the above implantable or insertable medical
devices as well as methods of making the above devices.

WO 2005/011767 A1

IMPLANTABLE OR INSERTABLE MEDICAL DEVICES
CONTAINING SILICONE COPOLYMER
FOR CONTROLLED DELIVERY OF THERAPEUTIC AGENTS

FIELD OF THE INVENTION

[0001] The present invention relates to implantable or insertable medical devices for controlled delivery of one or more therapeutic agents.

BACKGROUND OF THE INVENTION

[0002] Numerous medical devices have been developed for the delivery of therapeutic agents to the body.

[0003] In accordance with some delivery strategies, a therapeutic agent is provided (a) within a polymeric carrier layer and/or (b) beneath a polymeric barrier layer that is associated with an implantable or insertable medical device. Once the medical device is placed at the desired location within a patient, the therapeutic agent is released from the medical device at a rate that is dependent upon the nature of the polymeric carrier and/or barrier layer.

[0004] The desired release profile for the therapeutic agent is dependent upon the particular treatment at hand, including the specific condition being treated, the specific therapeutic agent selected, the specific site of administration, and so forth. Accordingly, there is a continuing need for polymeric materials that can serve as release regions, such as barrier layers and/or carrier layers, which are able to provide a range of therapeutic agent release rates.

SUMMARY OF THE INVENTION

[0005] The present invention is directed to novel implantable or insertable medical devices, which provide controlled release of a therapeutic agent.

[0006] According to a first aspect of the present invention, an implantable or insertable medical device is provided, which comprises (a) a therapeutic agent and (b) a polymeric release region that controls the release of the therapeutic agent upon administration to a patient. The polymeric release region comprises a silicone copolymer,

which contains a plurality of siloxane units and a plurality of non-siloxane units. The non-siloxane units can be, for example, low or elevated T_g non-siloxane units. The elevated T_g non-siloxane units of the silicone copolymer can correspond, for example, to vinyl monomers, aromatic monomers, methacrylic monomers, acrylic monomers and/or alkene monomers. The low T_g non-siloxane units of the silicone copolymer can correspond, for example, acrylic monomers, methacrylic monomers, vinyl ether monomers, cyclic ether monomers, ester monomers, unsaturated hydrocarbon monomers, and/or halogenated unsaturated hydrocarbon monomers.

[0007] The polymeric release region of the implantable or insertable medical device can be, for example, (a) a carrier region that comprises the therapeutic agent or (b) a barrier region that is disposed over a therapeutic-agent-containing region that comprises the therapeutic agent. In certain embodiments, the polymeric release region is in the form of a coating layer.

[0008] Where elevated T_g non-siloxane units are selected, the silicone copolymer beneficially has a first glass transition temperature that is greater than ambient temperature and a second glass transition temperature that is less than ambient temperature.

[0009] The silicone copolymer can be, for example, a block copolymer that comprises (a) one or more blocks of siloxane units and (b) one or more blocks of elevated T_g non-siloxane units. The block(s) of siloxane units can correspond, for example, to a rubbery phase within the release region at ambient temperatures, while the block(s) of elevated T_g non-siloxane units can correspond, for example, to a hard phase within the release layer at ambient temperatures. Examples of silicone block copolymers include diblock copolymers, triblock copolymers and graft copolymers.

[0010] Examples of implantable or insertable medical device include catheters, guide wires, balloons, filters, stents, stent grafts, vascular grafts, vascular patches, and shunts. The implantable or insertable medical device may be adapted for implantation or insertion into, for example, the coronary vasculature, peripheral vascular system, esophagus, trachea, colon, biliary tract, urinary tract, prostate or brain.

[0011] The therapeutic agent can be selected from any number of categories, including anti-thrombotic agents, anti-proliferative agents, anti-inflammatory agents, anti-migratory agents, agents affecting extracellular matrix production and organization,

antineoplastic agents, anti-mitotic agents, anesthetic agents, anti-coagulants, vascular cell growth promoters, vascular cell growth inhibitors, cholesterol-lowering agents, vasodilating agents, and agents that interfere with endogenous vasoactive mechanisms.

[0012] According to another aspect of the present invention, a method of forming the above implantable or insertable medical device is provided. The method comprises (a) providing a solution comprising the silicone copolymer and a solvent (which can comprise one or more solvent species); and (b) forming the release region from the solution by removing the solvent from the solution. Solvent spraying is one beneficial technique for forming the release region. In some embodiments (for example, where a carrier region is formed), the solution can further comprise the therapeutic agent in dissolved or dispersed form. In other embodiments (for example, where a barrier region is formed), the solution is applied over a therapeutic-agent-containing region.

[0013] According to another aspect of the present invention, a method is provided for releasing a therapeutic agent within a patient. The method comprises (a) providing an implantable or insertable medical device like that above, (b) implanting or inserting the therapeutic-agent-releasing medical device of into the patient. In certain embodiments, the medical device is inserted into the vasculature, where the therapeutic agent is released for example, in the treatment of restenosis.

[0014] One advantage of the present invention is that implantable or insertable medical devices can be provided, which give or result in controlled release of a therapeutic agent.

[0015] Another advantage of the present invention is that a variety of materials can be provided, which can be used in release regions of implantable or insertable medical devices.

[0016] Another advantage of the present invention is that implantable or insertable medical devices can be provided, which are relatively resistant to the effects of radiation sterilization, particularly where quantities of radiation are used that are effective to kill pathogens.

[0017] These and other embodiments and advantages of the present invention will become immediately apparent to those of ordinary skill in the art upon review of the Detailed Description and Claims to follow.

DETAILED DESCRIPTION OF THE INVENTION

[0018] The present invention relates to implantable or insertable medical devices that comprise (a) a therapeutic agent and (b) a polymeric release region comprising a silicone copolymer, which release region controls the release of the therapeutic agent upon administration to a patient.

[0019] The polymeric release region can be provided in a number of configurations. For example, the polymeric release region can constitute the entirety of the medical device, or it can constitute only a portion of the medical device. The portion of the medical device can be, for example, one or more medical device layers (e.g., one or more coating layers), one or medical device components or portions thereof, and so forth.

[0020] By "release region" is meant a region that regulates the rate of release of a therapeutic agent. Release regions are commonly either carrier regions or barrier regions. A "carrier region" is a region which contains at least one therapeutic agent and from which the therapeutic agent is released. A "barrier region" is a region that is disposed between a source of therapeutic agent and a site of intended release, which controls the rate at which the therapeutic agent is released.

[0021] For instance, in some embodiments of the present invention, an outer carrier layer is disposed over at least a portion of an implantable or insertable medical device substrate. Upon implantation or insertion of the device, the therapeutic agent is released from the carrier layer in a controlled fashion. In other embodiments, a therapeutic-agent-containing layer and a barrier layer are provided over at least a portion of an implantable or insertable medical device substrate. Because the barrier layer is disposed over the therapeutic-agent-containing layer, the barrier layer acts to control release of the therapeutic agent from the medical device upon implantation or insertion of the same.


[0022] Preferred implantable or insertable medical devices for use in conjunction with the present invention include catheters (for example, renal or vascular catheters such as balloon catheters), guide wires, balloons, filters (e.g., vena cava filters), stents (including coronary vascular stents, cerebral, urethral, ureteral, biliary, tracheal, gastrointestinal and esophageal stents), stent grafts, cerebral aneurysm filler coils (including Guglielmi detachable coils and metal coils), vascular grafts, myocardial plugs, patches, pacemakers and pacemaker leads, heart valves, biopsy devices, or any coated substrate (which can comprise, for example, glass, metal, polymer, ceramic and

combinations thereof) that is implanted or inserted into the body, either for procedural use or as an implant, and from which therapeutic agent is released.

[0023] The medical devices contemplated for use in connection with the present invention include drug delivery medical devices that are used for either systemic treatment or for the localized treatment of any mammalian tissue or organ. Non-limiting examples are tumors; organs including but not limited to the heart, coronary and peripheral vascular system (referred to overall as "the vasculature"), lungs, trachea, esophagus, brain, liver, kidney, bladder, urethra and ureters, eye, intestines, stomach, pancreas, ovary, and prostate; skeletal muscle; smooth muscle; breast; cartilage; and bone.

[0024] One particularly preferred medical device for use in connection with the present invention is a vascular stent that delivers therapeutic agent into the vasculature for the treatment of restenosis. As used herein, "treatment" refers to the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination a disease or condition. Preferred subjects are mammalian subjects and more preferably human subjects.


[0025] As previously noted, the polymeric release region of the present invention comprises a silicone copolymer. A "polymer" is a molecule having one or more chains within which multiple copies of one or more constitutional units are found. A specific



example of a polymer is polystyrene

in which n styrene constitutional

units are found. A copolymer is a polymer that contains at least two dissimilar constitutional units. A "silicone copolymer" is polymer comprising two or more dissimilar constitutional units, at least one of which is a siloxane



unit:

and at least one of which is not. Each of the two or more dissimilar constitutional units is repeated within the molecule, preferably at least 10 times, and more preferably at least 50, 100 or 500 or more times.

[0026] In the siloxane unit, R₁ and R₂ are organic radicals, for example, linear,

branched or cyclic alkyl groups (e.g., methyl groups, ethyl groups, propyl groups, isopropyl groups, butyl groups, isobutyl groups, sec-butyl groups, tert-butyl groups, cyclohexyl groups and so forth), which may be substituted or unsubstituted, as well as substituted or unsubstituted aryl groups (e.g., phenyl groups, p-, m- or o-alkyl-substituted phenyl groups and so forth). R_1 and R_2 can be the same or different.

[0027] Such copolymers may include (a) one or more chains containing repeating constitutional units of a single type (e.g., block copolymers), (b) one or more chains containing randomly distributed constitutional units of two or more types (e.g., random copolymers), (c) one or more chains containing two or more constitutional units that repeat within an ongoing series (e.g., alternating copolymers), and so forth.

[0028] The copolymers of the present invention may be provided in a variety of configurations, including cyclic, linear and branched configurations. Branched configurations include star-shaped configurations (e.g., configurations in which three or more chains emanate from a single branch point), comb configurations (e.g., graft copolymers having a main chain and a plurality of branching side chains) and dendritic configurations (including arborescent or hyperbranched copolymers).

[0029] The silicone copolymers of the present invention typically have an elongation at break of at least 25% at ambient temperature. "Elongation" is an increase in length of a test specimen under tension, stated herein as a percentage of the original length. The "elongation at break" is the amount of elongation that is observed at the point where the specimen breaks or otherwise fails under tension. Ambient temperature is typically 25°C-45°C, more typically body temperature (e.g., 35°C-40°C).

[0030] In some embodiments, the non-siloxane units of the silicone copolymers that are used in connection with the present invention are elevated T_g non-siloxane units. By "elevated T_g non-siloxane unit" is meant a constitutional unit that corresponds to a monomer, which can display either (a) a glass transition temperature (T_g), as measured by any of a number of techniques including differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA), or dielectric analysis (DEA), that is above ambient temperature when the monomer is in homopolymer form or (b) a melting point (T_m), as measured by any of a number of techniques including differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA), or dielectric analysis (DEA), that is above ambient temperature when the monomer is in homopolymer form.

[0031] In some embodiments, the non-siloxane units of the silicone copolymers that are used in connection with the present invention are low T_g non-siloxane units. By "low T_g non-siloxane unit" is meant a constitutional unit that corresponds to a monomer, which can display a glass transition temperature (T_g), as measured by any of a number of techniques including those discussed above, that is below ambient temperature when the monomer is polymerized as a homopolymer.

[0032] Numerous non-siloxane units can be used in connection with the silicone copolymers of the present invention.

[0033] The elevated T_g non-siloxane units can be those that correspond to, for example, vinyl aromatic monomers, other vinyl monomers, other aromatic monomers, methacrylic monomers, acrylic monomers, and alkene monomers.

[0034] Vinyl aromatic monomers are those having aromatic and vinyl moieties and include unsubstituted monomers, vinyl-substituted monomers and ring-substituted monomers. Suitable vinyl aromatic monomers include the following (listed along with a published homopolymer T_g and, in some instances, a published homopolymer T_m): (a) unsubstituted vinyl aromatics, such as atactic styrene (T_g 100°C), isotactic styrene (T_g 100°C) (T_m 240°C) and 2-vinyl naphthalene (T_g 151°C), (b) vinyl substituted aromatics such as α -methyl styrene, (c) ring-substituted vinyl aromatics including (i) ring-alkylated vinyl aromatics such as 3-methylstyrene (T_g 97°C), 4-methylstyrene (T_g 97°C), 2,4-dimethylstyrene (T_g 112°C), 2,5-dimethylstyrene (T_g 143°C), 3,5-dimethylstyrene (T_g 104°C), 2,4,6-trimethylstyrene (T_g 162°C), and 4-tert-butylstyrene (T_g 127°C), (ii) ring-alkoxylated vinyl aromatics, such as 4-methoxystyrene (T_g 113°C) and 4-ethoxystyrene (T_g 86°C), (iii) ring-halogenated vinyl aromatics such as 2-chlorostyrene (T_g 119°C), 3-chlorostyrene (T_g 90°C), 4-chlorostyrene (T_g 110°C), 2,6-dichlorostyrene (T_g 167°C), 4-bromostyrene (T_g 118°C) and 4-fluorostyrene (T_g 95°C) and (iv) ester-substituted vinyl aromatics such as 4-acetoxystyrene (T_g 116°C).

[0035] Other suitable vinyl monomers include the following: (a) vinyl alcohol (T_g 85°C) (T_m 220°C); (b) vinyl esters such as vinyl benzoate (T_g 71°C), vinyl 4-tert-butyl benzoate (T_g 101°C), vinyl cyclohexanoate (T_g 76°C), vinyl pivalate (T_g 86°C), vinyl trifluoroacetate (T_g 46°C), vinyl butyral (T_g 49°C) (T_m 322°C), (c) vinyl amines such as 2-vinyl pyridine (T_g 104°C), 4-vinyl pyridine (T_g 142°C), and vinyl carbazole (T_g 227°C) (T_m 320°C), (d) vinyl halides such as vinyl chloride (T_g 81°C) (T_m 227°C) and vinyl

fluoride (T_g 40°C) (T_m 171°C); (e) alkyl vinyl ethers such as methyl vinyl ether (T_g -31°C) (T_m 144°C), propyl vinyl ether (T_g -49°C) (T_m 76°C), butyl vinyl ether (T_g -55°C) (T_m 64°C), isobutyl vinyl ether (T_g -19°C) (T_m 165°C), tert-butyl vinyl ether (T_g 88°C) (T_m 250°C) and cyclohexyl vinyl ether (T_g 81°C), and (f) other vinyl compounds such as 1-vinyl-2-pyrrolidone (T_g 54°C) and vinyl ferrocene (T_g 189°C).

[0036] Suitable aromatic monomers, other than vinyl aromatics, include acenaphthalene (T_g 214°C) and indene (T_g 85°C).

[0037] Suitable methacrylic monomers include (a) methacrylic acid (T_g 228°C), (b) methacrylic acid salts such as sodium methacrylate (T_g 310°C), (c) methacrylic acid anhydride (T_g 159°C), (d) methacrylic acid esters (methacrylates) including (i) alkyl methacrylates such as atactic methyl methacrylate (T_g 105-120°C), syndiotactic methyl methacrylate (T_g 115°C) (T_m 200°C), ethyl methacrylate (T_g 65°C), isopropyl methacrylate (T_g 81°C), isobutyl methacrylate (T_g 53°C), t-butyl methacrylate (T_g 118°C) and cyclohexyl methacrylate (T_g 92°C), (ii) aromatic methacrylates such as phenyl methacrylate (T_g 110°C) and including aromatic alkyl methacrylates such as benzyl methacrylate (T_g 54°C), (iii) hydroxyalkyl methacrylates such as 2-hydroxyethyl methacrylate (T_g 57°C) and 2-hydroxypropyl methacrylate (T_g 76°C), (iv) additional methacrylates including isobornyl methacrylate (T_g 110°C) and trimethylsilyl methacrylate (T_g 68°C), and (e) other methacrylic-acid derivatives including methacrylonitrile (T_g 120°C).

[0038] Suitable acrylic monomers include (a) acrylic acid (T_g 105°C), its anhydride and salt forms, such as potassium acrylate (T_g 194°C) and sodium acrylate (T_g 230°C); (b) certain acrylic acid esters such as isopropyl acrylate (T_g -11°C) (T_m 162°C), tert-butyl acrylate (T_g 43-107°C) (T_m 193°C), hexyl acrylate (T_g 57°C) and isobornyl acrylate (T_g 94°C); (c) acrylic acid amides such as acrylamide (T_g 165°C), N-isopropylacrylamide (T_g 85-130°C) and N,N dimethylacrylamide (T_g 89°C); and (d) other acrylic-acid derivatives including acrylonitrile (T_g 125°C) (T_m 319°C).

[0039] Suitable alkene based monomers include the following: ethylene (HDPE) (T_g -125°C) (T_m 130°C), isotactic propylene (T_g -8°C) (T_m 176°C), 4-methyl pentene (T_g 29°C) (T_m 250°C), 1-octadecene (T_g 55°C), and tetrafluoroethylene (T_g 117°C) (T_m 327°C).

[0040] Low T_g non-siloxane units can be those that correspond to, for example,

acrylic monomers, methacrylic monomers, vinyl ether monomers, cyclic ether monomers, ester monomers, unsaturated hydrocarbon monomers, halogenated unsaturated hydrocarbon monomers, and other monomers.

[0041] Suitable acrylic monomers include (a) alkyl acrylates such as methyl acrylate (T_g 10°C), ethyl acrylate (T_g -24°C), propyl acrylate, isopropyl acrylate (T_g -11°C, isotactic), butyl acrylate (T_g -54°C), sec-butyl acrylate (T_g -26°C), isobutyl acrylate (T_g -24°C), cyclohexyl acrylate (T_g 19°C), 2-ethylhexyl acrylate (T_g -50°C), dodecyl acrylate (T_g -3°C) and hexadecyl acrylate (T_g 35°C), (b) arylalkyl acrylates such as benzyl acrylate (T_g 6°C), (c) alkoxyalkyl acrylates such as 2-ethoxyethyl acrylate (T_g -50°C) and 2-methoxyethyl acrylate (T_g -50°C), (d) halo-alkyl acrylates such as 2,2,2-trifluoroethyl acrylate (T_g -10°C) and (e) cyano-alkyl acrylates such as 2-cyanoethyl acrylate (T_g 4°C).

[0042] Suitable methacrylic monomers include (a) alkyl methacrylates such as butyl methacrylate (T_g 20°C), hexyl methacrylate (T_g -5°C), 2-ethylhexyl methacrylate (T_g -10°C), octyl methacrylate (T_g -20°C), dodecyl methacrylate (T_g -65°C), hexadecyl methacrylate (T_g 15°C) and octadecyl methacrylate (T_g -100°C) and (b) aminoalkyl methacrylates such as diethylaminoethyl methacrylate (T_g 20°C) and 2-tert-butyl-aminoethyl methacrylate (T_g 33°C).

[0043] Suitable vinyl ether monomers include (a) alkyl vinyl ethers such as methyl vinyl ether (T_g -31°C), ethyl vinyl ether (T_g -43°C), propyl vinyl ether (T_g -49 °C), butyl vinyl ether (T_g -55°C), isobutyl vinyl ether (T_g -19°C), 2-ethylhexyl vinyl ether (T_g -66°C) and dodecyl vinyl ether (T_g -62°C).

[0044] Suitable cyclic ether monomers include tetrahydrofuran (T_g -84°C), trimethylene oxide (T_g -78°C), ethylene oxide (T_g -66°C), propylene oxide (T_g -75°C), methyl glycidyl ether (T_g -62°C), butyl glycidyl ether (T_g -79°C), allyl glycidyl ether (T_g -78°C), epibromohydrin (T_g -14°C), epichlorohydrin (T_g -22°C), 1,2-epoxybutane (T_g -70°C), 1,2-epoxyoctane (T_g -67°C) and 1,2-epoxydecane (T_g -70°C).

[0045] Suitable ester monomers (other than acrylates and methacrylates) include ethylene malonate (T_g -29°C), vinyl acetate (T_g 30°C), and vinyl propionate (T_g 10 °C).

[0046] Suitable unsaturated hydrocarbon monomers include ethylene, propylene (T_g -8 to -13°C), isobutylene (T_g -73°C), 1-butene (T_g -24°C), trans-butadiene (T_g -58°C), 4-methyl pentene (T_g 29°C), 1-octene (T_g -63°C) and other α -olefins, cis-isoprene (T_g -63°C), and trans-isoprene (T_g -66°C).

[0047] Suitable halogenated unsaturated hydrocarbon monomers include vinylidene chloride (T_g -18°C), vinylidene fluoride (T_g -40°C), cis-chlorobutadiene (T_g -20°C), and trans-chlorobutadiene (T_g -40°C).

[0048] Suitable additional monomers include ϵ -caprolactone (T_g -60°C).

[0049] In many embodiments, the copolymers will comprise (a) one or more polysiloxane chains that result in the formation of a rubbery phase within the release region at ambient temperatures and (b) one or more elevated T_g non-siloxane chains that result in the formation of a hard phase within the release region at ambient temperatures.

[0050] Some exemplary copolymers are block copolymers comprising (a) one or more polysiloxane (silicone) blocks (e.g., one or more blocks of polydimethylsiloxane (T_g -127°C) (T_m -40 °C), polydiethylsiloxane, polymethylethylsiloxane, polymethylphenylsiloxane (T_g -86 °C), and/or polydiphenylsiloxane) and (b) one or more blocks of elevated T_g non-siloxane units such as those listed above.

[0051] One preferred group of block copolymers has (a) a silicon midblock or main chain, which can be for example, a block of polydimethylsiloxane, polymethylphenylsiloxane or polydiphenylsiloxane having a linear, star or branched configuration, and (b) one or more elevated T_g endblocks or side chains, which can be for example blocks of polystyrene or poly(alkyl methacrylate).


[0052] Two particularly preferred copolymers are: (a) graft copolymers having a silicone main chain and polystyrene side chains, and (b) triblock copolymers having a silicone midblock and a polystyrene endblocks.

[0053] The latter are similar in some ways to known polystyrene-polyisobutylene-polystyrene triblock copolymers (SIBS copolymers), such as are described in United States Patent Application 20020107330 and United States Patent No. 6,545,097 entitled "Drug delivery compositions and medical devices containing block copolymer", in that both polymers are thermoplastic elastomers having an elastomeric center block and phase separated, hard polystyrene end blocks.

[0054] Implantable or insertable medical devices are typically sterilized by exposure to ethylene oxide or to radiation such as gamma or electron beam radiation. Certain therapeutic agents, however, are unstable under ethylene oxide sterilization conditions. On the other hand, radiation sterilization can lead to chain scission and/or crosslinking of polymers within the medical device, leading to changes in the chemical, physical, and


drug-eluting properties of the polymers. For instance, radiation can lead to an unacceptable increase in the surface tack of the material, which can in turn cause defects in the polymer if it is expanded (e.g., when it is in the form of a coating on the surface of an expandable stent or balloon). Silicone blocks, while not being completely immune to radiation damage, are significantly less susceptible to radiation damage than are polyisobutylene blocks, which are known to undergo chain scission during irradiation, especially at the radiation levels used for medical device sterilization (e.g., about 2.5 Mrad). Hence, in this embodiment of the present invention, a material is provided, which has properties that are analogous to SIBS copolymers, while also exhibiting improved immunity to radiation-based changes in polymer properties. The polystyrene-silicone-polystyrene copolymers in this embodiment of the invention are also believed to exhibit outstanding biocompatibility, due to the biocompatibility of the silicone and polystyrene blocks that make up the copolymer.

[0055] The silicone copolymers of the present invention can be synthesized using a variety of synthesis schemes. For example, a silicone copolymer can be prepared using hydrosilylation chemistry by reacting a dihydride-terminated poly(dimethylsiloxane) with a methacrylate-terminated poly(styrene) in the presence of a platinum catalyst along the following lines:



[0056] A similar reaction scheme can be used to construct a silicone copolymer

having polystyrene grafts along the following lines (only a single polystyrene graft is illustrated):



[0057] Of course, other reaction chemistries are suitable for the practice of the present invention besides platinum-catalyzed hydrosilylation chemistries, for instance, cationic polymerization, anionic polymerization, Ziegler-Natta polymerization, metallocene polymerization, free-radical polymerization, nitroxide-mediated polymerization (NMP), atom transfer radical polymerization (ATRP), and reversible addition-fragmentation chain transfer (RAFT) polymerization chemistries.

[0058] For example, a silicone block can be provided with terminal unsaturation (e.g., a terminal vinyl group). At the same time, a non-siloxane block can also be provided with terminal unsaturation (e.g., a terminal vinyl or methacrylate group). The silicone and non-silicone blocks can then be linked using one of the above reaction chemistries.

[0059] As a more specific example, a linear, star-shaped or dendritic copolymer can

be formed by reacting (a) a linear, star-shaped or dendritic silicone block, whose end groups are unsaturated, with (b) a linear non-siloxane block having a single unsaturated end group. The reaction can be conducted using, for example, a metallocene catalyst.

[0060] Siloxane/styrene diblock copolymers have reportedly been synthesized via NMP. See S.K. Pollack, D.U. Singer and A.M. Morgan, "Siloxane/Styrene Diblock Copolymers via Nitroxide Mediated Radical Polymerization", *ACS Polymer Preprints*, 40(2), 370, (1999).

[0061] Graft copolymers can also be constructed, for example, by (a) reacting a silicone block having terminal unsaturation with a non-siloxane block having a number of unsaturated side groups, (b) reacting a non-siloxane block having terminal unsaturation with a silicone block having a number of unsaturated side groups, and (c) reacting a silicone block having terminal unsaturation with an unsaturated monomer (thus polymerizing the non-siloxane main chain *in situ*).

[0062] Poly(methylphenylsilane)-graft-poly(styrene) has reportedly been synthesized via ATRP, where bromomethylated poly(methylphenylsilane) is utilized as a macromolecular initiator in an ATRP of styrene. See S.J. Holder et al., "A convenient route to poly(methylphenylsilane)-graft-polystyrene copolymers," *Macromol. Chem., Phys.*, 1997, vol. 198, p. 3571.

[0063] Once the silicone copolymer is provided, numerous techniques are available for forming the polymeric release regions of the present invention. For example, where the selected copolymer has thermoplastic characteristics, a variety of standard thermoplastic processing techniques can be used to form the polymeric release region, including compression molding, injection molding, blow molding, spinning, vacuum forming and calendaring, as well as extrusion into sheets, fibers, rods, tubes and other cross-sectional profiles of various lengths.

[0064] Using these and other techniques, entire devices or portions thereof can be made. For example, an entire stent can be extruded using the above techniques. As another example, a coating can be provided by extruding a coating layer onto a pre-existing stent. As yet another example, a coating can be co-extruded along with an underlying stent body.

[0065] If the therapeutic agent is stable at processing temperatures, then it can be

combined with the copolymer prior to thermoplastic processing, producing a therapeutic-agent containing carrier region. If not, then a carrier region can nonetheless be formed by subsequent introduction of therapeutic agent as discussed below.

[0066] Polymeric release regions can also be formed using solvent-based techniques in which copolymer is first dissolved or dispersed in a solvent and the resulting mixture is subsequently used to form the polymeric release region.

[0067] Where solvent-based techniques are used, the solvent system that is selected will contain one or more solvent species. The solvent system preferably is a good solvent for the copolymer and, where included, for the therapeutic agent as well. The particular solvent species that make up the solvent system may also be selected based on other characteristics including drying rate and surface tension.

[0068] Preferred solvent-based techniques include, but are not limited to, solvent casting techniques, spin coating techniques, web coating techniques, solvent spraying techniques, dipping techniques, techniques involving coating via mechanical suspension including air suspension, ink jet techniques, electrostatic techniques, and combinations of these processes.

[0069] Typically, a mixture containing solvent and copolymer is applied to a substrate to form a release region. For example, the substrate can be all or a portion of an implantable or insertable medical device, such as a stent, to which a release layer is applied.

[0070] On the other hand, the substrate can also be, for example, a template from which the polymeric release region is removed after solvent elimination. Such template-based techniques are particularly appropriate for forming simple objects such as sheets, tubes, cylinders and so forth, which can be easily removed from a template substrate.

[0071] In other techniques, for example, fiber forming techniques, the polymeric release region is formed without the aid of a substrate or template.

[0072] Where appropriate, techniques such as those listed above can be repeated or combined to build up a release layer to a desired thickness. The thickness of the release layer can be varied in other ways as well. For example, in one preferred process, solvent spraying, coating thickness can be increased by modification of coating process parameters, including increasing spray flow rate, slowing the movement between the substrate to be coated and the spray nozzle, providing repeated passes and so forth.

[0073] Where a carrier region is formed (as opposed to, for example, a barrier region), a therapeutic agent can be dissolved or dispersed in the copolymer/solvent mixture if desired, and hence co-established with the carrier region. In other embodiments, on the other hand, the therapeutic agent can be dissolved or dispersed within a solvent, and the resulting solution contacted with a polymer region that is previously formed using, for example, one or more of the application techniques described above (e.g., dipping, spraying, etc.).

[0074] Barrier layers, on the other hand, are formed over a therapeutic-agent-containing region, for example, using solvent-based techniques such as those discussed above, wherein barrier polymer(s) is first dissolved or dispersed in a solvent, and the resulting mixture is subsequently used to form the barrier layer. In some embodiments, the therapeutic-agent-containing region will comprise one or more polymers, which can be selected, for example, from the polymers listed herein. As such, the therapeutic-agent-containing region can also be established using solvent-based techniques (e.g., dipping, spraying, etc.) such as those discussed above. In other embodiments, the therapeutic-agent-containing region beneath the barrier layer is established without an associated polymer. In this case, the therapeutic agent can simply be dissolved or dispersed in a solvent or liquid, and the resulting solution/dispersion can be contacted with a substrate again using, for instance, one or more of the above-described application techniques.

[0075] Where the release region is formed using a solvent-based technique, it is preferably dried after application to remove the solvents. The release region typically further conforms to any underlying surface during the drying process.

[0076] The medical devices of the present invention are typically sterilized using conventional processes such as exposure to ethylene oxide or radiation such as gamma or electron beam radiation. Certain therapeutic agents, however, are unstable under ethylene oxide sterilization conditions. In such cases, radiation sterilization is typically used, in which case chain scission and/or crosslinking of the silicone copolymer is addressed, either by taking into account the chemical and physical property changes that occur or by selecting a silicone copolymer that is relatively resistant to radiation sterilization.

[0077] The release profile associated with the release region can be modified in a number of ways, including (a) changing the type of siloxane unit(s) and/or non-siloxane unit(s) within the copolymer, (b) changing the ratio of siloxane unit(s) to non-siloxane

unit(s) within the copolymer, (c) changing the molecular weight of the copolymer, (d) changing the distribution of the siloxane and non-siloxane units within the copolymer (e.g., a block copolymer vs. a random copolymer vs. an alternating copolymer) and/or (e) changing the configuration of the polymer (e.g., a linear copolymer vs. a branched copolymer).

[0078] For example, the release profile of the therapeutic agent can be modified by increasing or decreasing the overall hydrophilicity of the copolymer (or, viewed conversely, decreasing or increasing the overall hydrophobicity). As a specific example, the hydrophilicity of a block copolymer containing one or more silicone blocks and one or more polystyrene blocks can be increased by replacing at least some of the polystyrene blocks (which are substantially hydrophobic) with blocks of a substantially hydrophilic material such as poly(1-vinyl-2-pyrrolidone).

[0079] The release profile can also be modified by varying the thickness of the release region. Moreover, multiple release regions can be employed to modify the release profile. In addition, where a carrier region is employed, a therapeutic-agent concentration gradient can be established within the carrier region to control release of therapeutic agent.

[0080] The release profile associated with the release region can also be modified by blending one or more supplementary polymers with the silicone copolymer within the release region, or by providing a separate barrier layer that contains one or more supplementary polymers. For example, supplementary polymer(s) can be selected and blended into the release region to vary the overall hydrophilicity of the same.

[0081] The supplementary polymers may be, for example, homopolymers or copolymers, crosslinked or uncrosslinked, linear or branched, natural or synthetic, thermoplastic or thermosetting. Supplementary polymers include the following: polycarboxylic acid polymers and copolymers including polyacrylic acids; acetal polymers and copolymers; acrylate and methacrylate polymers and copolymers (e.g., n-butyl methacrylate); cellulosic polymers and copolymers, including cellulose acetates, cellulose nitrates, cellulose propionates, cellulose acetate butyrates, cellophanes, rayons, rayon triacetates, and cellulose ethers such as carboxymethyl celluloses and hydroxyalkyl celluloses; polyoxymethylene polymers and copolymers; polyimide polymers and copolymers such as polyether block imides, polyamidimides, polyesterimides, and

polyetherimides; polysulfone polymers and copolymers including polyarylsulfones and polyethersulfones; polyamide polymers and copolymers including nylon 6,6, polycaprolactams and polyacrylamides; resins including alkyd resins, phenolic resins, urea resins, melamine resins, epoxy resins, allyl resins and epoxide resins; polycarbonates; polyacrylonitriles; polyvinylpyrrolidones (cross-linked and otherwise); polymers and copolymers of vinyl monomers including polyvinyl alcohols, polyvinyl halides such as polyvinyl chlorides, ethylene-vinylacetate copolymers (EVA), polyvinylidene chlorides, polyvinyl ethers such as polyvinyl methyl ethers, polystyrenes, styrene-maleic anhydride copolymers, styrene-butadiene copolymers, styrene-ethylene-butylene copolymers (e.g., a polystyrene-polyethylene/butylene-polystyrene (SEBS) copolymer, available as Kraton® G series polymers), acrylonitrile-styrene copolymers, acrylonitrile-butadiene-styrene copolymers, styrene-butadiene copolymers and styrene-isobutylene copolymers (e.g., polyisobutylene-polystyrene block copolymers such as SIBS), polyvinyl ketones, polyvinylcarbazoles, and polyvinyl esters such as polyvinyl acetates; polybenzimidazoles; ionomers; polyalkyl oxide polymers and copolymers including polyethylene oxides (PEO); glycosaminoglycans; polyesters including polyethylene terephthalates and aliphatic polyesters such as polymers and copolymers of lactide (which includes lactic acid as well as d-,l- and meso lactide), epsilon-caprolactone, glycolide (including glycolic acid), hydroxybutyrate, hydroxyvalerate, para-dioxanone, trimethylene carbonate (and its alkyl derivatives), 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, and 6,6-dimethyl-1,4-dioxan-2-one (a copolymer of polylactic acid and polycaprolactone is one specific example); polyether polymers and copolymers including polyarylethers such as polyphenylene ethers, polyether ketones, polyether ether ketones; polyphenylene sulfides; polyisocyanates; polyolefin polymers and copolymers, including polyalkylenes such as polypropylenes, polyethylenes (low and high density, low and high molecular weight), polybutylenes (such as polybut-1-ene and polyisobutylene), poly-4-methyl-pen-1-enes, ethylene-alpha-olefin copolymers, ethylene-methyl methacrylate copolymers and ethylene-vinyl acetate copolymers; fluorinated polymers and copolymers, including polytetrafluoroethylenes (PTFE), poly(tetrafluoroethylene-co-hexafluoropropene) (FEP), modified ethylene-tetrafluoroethylene copolymers (ETFE), and polyvinylidene fluorides (PVDF); silicone polymers and copolymers; polyurethanes; p-xylylene polymers; polyiminocarbonates; copoly(ether-esters) such as polyethylene

oxide-poly(lactic acid) copolymers; polyphosphazines; polyalkylene oxalates; polyoxaamides and polyoxaesters (including those containing amines and/or amido groups); polyorthoesters; biopolymers, such as polypeptides, proteins, polysaccharides and fatty acids (and esters thereof), including fibrin, fibrinogen, collagen, elastin, chitosan, gelatin, starch, glycosaminoglycans such as hyaluronic acid; as well as blends and copolymers of the above.

[0082] Medical devices having a sustained release profile are preferred in many cases. By "sustained release profile" is meant a release profile in which less than 25% of the total release from the medical device that occurs over the course of implantation/insertion in the body occurs within the first 1, 2, 3 or even more days of administration. Conversely, this means that more than 75% of the total release from the medical device will occur in a controlled fashion after the device has been implanted/inserted for the same period.

[0083] The release characteristics that are ultimately of interest are of course the release characteristics within the subject, for example, within a mammalian subject. However, it is well known in the art to test the release characteristics within an experimental system that gives a good indication of the actual release characteristics within the subject. For example, aqueous buffer systems are commonly used for testing release of therapeutic agents from vascular devices.

[0084] "Therapeutic agents", "pharmaceutically active agents", "pharmaceutically active materials", "drugs" and other related terms may be used interchangeably herein and include genetic therapeutic agents, non-genetic therapeutic agents and cells. Therapeutic agents may be used singly or in combination.

[0085] Exemplary non-genetic therapeutic agents for use in connection with the present invention include: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and

ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promoters; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (l) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; and (o) agents that interfere with endogenous vasoactive mechanisms.

[0086] Exemplary genetic therapeutic agents for use in connection with the present invention include anti-sense DNA and RNA as well as DNA coding for: (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin-like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ("TK") and other agents useful for interfering with cell proliferation. Also of interest is DNA encoding for the family of bone morphogenic proteins ("BMP's"), including BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNA's encoding them.

[0087] Vectors for delivery of genetic therapeutic agents include (a) plasmids, (b) viral vectors such as adenovirus, adenoassociated virus and lentivirus, and (c) non-viral vectors such as lipids, liposomes and cationic lipids.

[0088] Cells for use in connection with the present invention include cells of human origin (autologous or allogeneic), including stem cells, or from an animal source (xenogeneic), which can be genetically engineered, if desired, to deliver proteins of interest.

[0089] Numerous therapeutic agents, not necessarily exclusive of those listed above, have been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis. Such agents are useful for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/Guanylate cyclase stimulants such as forskolin, as well as adenosine analogs, (d) catecholamine modulators including α -antagonists such as prazosin and bunazosine, β -antagonists such as propranolol and α/β -antagonists such as labetalol and carvedilol, (e) endothelin receptor antagonists, (f) nitric oxide donors/releasing molecules including organic nitrates/nitrites such as nitroglycerin, isosorbide dinitrate and amyl nitrite, inorganic nitroso compounds such as sodium nitroprusside, sydnonimines such as molsidomine and linsidomine, nonoates such as diazenium diolates and NO adducts of alkanediamines, S-nitroso compounds including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), as well as C-nitroso-compounds, O-nitroso-compounds, N-nitroso-compounds and L-arginine, (g) ACE inhibitors such as cilazapril, fosinopril and enalapril, (h) ATII-receptor antagonists such as saralasin and losartin, (i) platelet adhesion inhibitors such as albumin and polyethylene oxide, (j) platelet aggregation inhibitors including aspirin and thienopyridine (ticlopidine, clopidogrel) and GP IIb/IIIa inhibitors

such as abciximab, eptifibatide and tirofiban, (k) coagulation pathway modulators including heparinoids such as heparin, low molecular weight heparin, dextran sulfate and β -cyclodextrin tetradecasulfate, thrombin inhibitors such as hirudin, hirulog, PPACK(D-phe-L-propyl-L-arg-chloromethylketone) and argatroban, FXa inhibitors such as antistatin and TAP (tick anticoagulant peptide), Vitamin K inhibitors such as warfarin, as well as activated protein C, (l) cyclooxygenase pathway inhibitors such as aspirin, ibuprofen, flurbiprofen, indomethacin and sulfinpyrazone, (m) natural and synthetic corticosteroids such as dexamethasone, prednisolone, methprednisolone and hydrocortisone, (n) lipoxygenase pathway inhibitors such as nordihydroguaiaretic acid and caffeic acid, (o) leukotriene receptor antagonists, (p) antagonists of E- and P-selectins, (q) inhibitors of VCAM-1 and ICAM-1 interactions, (r) prostaglandins and analogs thereof including prostaglandins such as PGE1 and PGI2 and prostacyclin analogs such as ciprostone, epoprostenol, carbacyclin, iloprost and beraprost, (s) macrophage activation preventers including bisphosphonates, (t) HMG-CoA reductase inhibitors such as lovastatin, pravastatin, fluvastatin, simvastatin and cerivastatin, (u) fish oils and omega-3-fatty acids, (v) free-radical scavengers/antioxidants such as probucol, vitamins C and E, ebselen, trans-retinoic acid and SOD mimics, (w) agents affecting various growth factors including FGF pathway agents such as bFGF antibodies and chimeric fusion proteins, PDGF receptor antagonists such as trapidil, IGF pathway agents including somatostatin analogs such as angiopeptin and ocreotide, TGF- β pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF- β antibodies, EGF pathway agents such as EGF antibodies, receptor antagonists and chimeric fusion proteins, TNF- α pathway agents such as thalidomide and analogs thereof, Thromboxane A2 (TXA2) pathway modulators such as sulotroban, vapiprost, dazoxiben and ridogrel, as well as protein tyrosine kinase inhibitors such as tyrphostin, genistein and quinoxaline derivatives, (x) MMP pathway inhibitors such as marimastat, ilomastat and metastat, (y) cell motility inhibitors such as cytochalasin B, (z) antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, which is a chlorinated purine nucleoside analog), pyrimidine analogs (e.g., cytarabine and 5-fluorouracil) and methotrexate, nitrogen mustards, alkyl sulfonates, ethylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas, cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, paclitaxel and

epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), rapamycin, cerivastatin, flavopiridol and suramin, (aa) matrix deposition/organization pathway inhibitors such as halofuginone or other quinazolinone derivatives and tranilast, (bb) endothelialization facilitators such as VEGF and RGD peptide, and (cc) blood rheology modulators such as pentoxifylline.

[0090] Numerous additional therapeutic agents useful for the practice of the present invention are also disclosed in U.S. Patent No. 5,733,925 assigned to NeoRx Corporation, the entire disclosure of which is incorporated by reference.

[0091] A wide range of therapeutic agent loadings can be used in connection with the medical devices of the present invention, with the amount of loading being readily determined by those of ordinary skill in the art and ultimately depending, for example, upon the condition to be treated, the nature of the therapeutic agent itself, the means by which the therapeutic agent is administered to the intended subject, and so forth.

[0092] The invention is further described with reference to the following non-limiting Example.

EXAMPLE

Synthesis and Characterization of Polydimethylsiloxane-Graft-Polystyrene Copolymer and Polystyrene-Polydimethylsiloxane-Polystyrene Triblock Copolymer

[0093] Polydimethylsiloxane-co-polystyrene graft and triblock copolymers are thermoplastic elastomers where the polydimethylsiloxane segments are elastomeric and the polystyrene chains form physical crosslinks. The synthesis of these copolymers involves two steps. The first step involves synthesizing a polydimethylsiloxane macroinitiator. The triblock copolymer can be synthesized by reacting a hydride-terminated polydimethylsiloxane with vinyl benzyl chloride. This leaves a benzyl chloride group at both chain ends. The graft copolymer is synthesized from a macroinitiator made from vinyl benzyl chloride and a polydimethylsiloxane-co-polymethylhydrogen siloxane. In this case, the benzyl chloride groups are located along

the polymer backbone. These polydimethylsiloxane macroinitiators can then be used to polymerize styrene monomer using atom transfer radical polymerization (ATRP). The polystyrene chains will grow from the benzyl chloride initiating groups located on the polymer chain. The molecular weight of the polystyrene chains can be controlled using ATRP.

[0094] Macroinitiator synthesis. Inhibitor is removed from vinyl benzylchloride (*m,p* isomers) by passing the vinyl benzylchloride through an inhibitor removal column (Aldrich –306312). The vinyl benzylchloride is collected in a tared vial. A two neck round bottom flask is charged with polydimethylsiloxane-co-polymethylhydrogensiloxane (MW = 1,600, 25-30mol% methylhydrogen siloxane), vinyl benzylchloride, toluene, and platinum catalyst (i.e., platinum-divinyltetramethyldisiloxane complex). The round bottom flask is also equipped with a stopcock. The flask is fitted with a magnetic stir bar, thermometer and reflux condenser, and the reaction mixture is stirred until the polystyrene dissolves. The solution is heated to 50°C for one hour. The reaction is conducted under air. The solution is allowed to cool to room temperature and is precipitated into ethanol. The extent of reaction is determined by the disappearance of the silicone-hydride bond at 2158 cm⁻¹ using FT-IR. A benzyl chloride-terminated polydimethylsiloxane macroinitiator is synthesized by the same procedure except that hydride-terminated polydimethylsiloxane (MW = 62,000) is used. A benzyl chloride-grafted polydimethylsiloxane macroinitiator is synthesized by the same procedure except that polydimethylsiloxane-co-polymethylhydrogen siloxane (0.5-1.0mol% polymethylhydrogen siloxane (MW = 55,000)) is used.

[0095] Copolymer synthesis. Inhibitor is removed from styrene by passing the styrene through a column of neutral alumina (Aldrich – 199974). The styrene is collected in a tared vial. A two neck round bottom flask is fitted with a magnetic stir bar, thermometer and reflux condenser. The flask is charged with macroinitiator (see above), styrene, copper (I) chloride, and 4,4'-dinonyl-2,2'-bipyridine. The round bottom flask is also equipped with a stopcock. The reaction mixture is stirred until it turns dark red in color, after which the solution is sparged with nitrogen for thirty minutes. The reaction solution is heated to 130°C, and the reaction is allowed to proceed for twenty hours. The solution is then allowed to cool below 80°C before adding toluene to dilute the polymer. Upon exposure to air the reaction solution turns green in color. The polymer solution is

cooled to room temperature and passed through a column of neutral alumina to remove the metal complex. The polymer solution is then precipitated into ethanol and the polymer precipitate is filtered.

[0096] Stent coatings. Solutions are provided that contain 5 wt% tetrahydrofuran (THF), 94 wt% toluene, 0.25 wt% paclitaxel and 0.75 wt% polymer. All solutions are prepared by mixing the polymer with the toluene and heating to 70°C for about an hour, cooling to room temperature, adding the THF, adding the paclitaxel, thoroughly mixing (e.g., overnight), and filtering. The following solutions are made: (1) a solution containing 0.75 wt% polystyrene-polydimethylsiloxane-polystyrene triblock copolymer, (2) a solution containing 0.75 wt% polydimethylsiloxane-graft-polystyrene copolymer, and (3) a solution containing 0.75 wt% polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), as described in United States Patent Application 20020107330 and United States Patent No. 6,545,097 entitled "Drug delivery compositions and medical devices containing block copolymer,"

[0097] Solutions are also provided that contain 5 wt% tetrahydrofuran (THF), 94 wt% toluene, 0.10 wt% paclitaxel and 0.90 wt% polymer. All solutions are prepared by mixing the polymer with the toluene and heating to 70°C for about an hour, adding the THF, adding the paclitaxel, thoroughly mixing (e.g., overnight), and filtering. The following solutions are made: (1) a solution containing 0.90 wt% polystyrene-polydimethylsiloxane-polystyrene triblock copolymer, (2) a solution containing 0.90 wt% polydimethylsiloxane-graft-polystyrene copolymer, (3) a solution containing 0.90 wt% SIBS.

[0098] Each solution is then placed in a syringe pump and fed to a spray nozzle. A stent is mounted onto a holding device parallel to the nozzle and rotated to ensure uniform coverage. Depending on the spray equipment used, either the stent or spray nozzle can be moved while spraying such that the nozzle moves along the stent while spraying for one or more passes. After a carrier coating is formed in this fashion, the stent is dried, for example, by placing it in a preheated oven for 30 minutes at 65°C, followed by 3 hours at 70°C. 8 stents are formed in this manner for each of the solutions.

[0099] Radiation stability. Polystyrene-polydimethylsiloxane-polystyrene triblock copolymer is subjected to electron beam radiation to evaluate the effect of radiation on the stability of the copolymer. The triblock copolymer is exposed to electron beam

radiation at a dose of 25 kilograys. The polydispersity index and the molecular weight of the copolymer, both before and after irradiation, are determined by gel permeation chromatography (GPC) using tetrahydrofuran as the mobile phase. Molecular weight and polydispersity data are summarized in the table below.

Sample	Mn	PDI
Triblock copolymer (before irradiation)	6800	6.70
Triblock copolymer (after irradiation)	6400	6.90

[0100] As can be seen from the above table, there is only a slight reduction in number average molecular (Mn) and a slight increase in polydispersity index (PDI) upon exposure to irradiation. Specifically, a decrease of 5.8% in Mn and an increase of 2.8% in PDI are observed. Accordingly, the triblock copolymer is considered radiation stable.

[0101] Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.

IN THE CLAIMS:

1. An implantable or insertable medical device comprising (a) a therapeutic agent and (b) a polymeric release region that controls the release of said therapeutic agent upon administration to a patient, said polymeric release region comprising a silicone copolymer comprising a plurality of siloxane units and a plurality of non-siloxane units.
2. The implantable or insertable medical device of claim 1, wherein said polymeric release region is a carrier region that comprises said therapeutic agent.
3. The implantable or insertable medical device of claim 1, wherein said polymeric release region is a barrier region disposed over a therapeutic-agent-containing region that comprises said therapeutic agent.
4. The implantable or insertable medical device of claim 1, wherein said polymeric release region is in the form of a coating layer that covers all or a part of said medical device.
5. The implantable or insertable medical device of claim 1, wherein said implantable or insertable medical device is selected from a catheter, a guide wire, a balloon, a filter, a stent, a stent graft, a vascular graft, a vascular patch and a shunt.
6. The implantable or insertable medical device of claim 1, wherein said implantable or insertable medical device is adapted for implantation or insertion into the coronary vasculature, peripheral vascular system, esophagus, trachea, colon, biliary tract, urinary tract, prostate or brain.
7. The implantable or insertable medical device of claim 1, wherein said therapeutic agent is selected from one or more of the group consisting of anti-thrombotic agents, anti-proliferative agents, anti-inflammatory agents, anti-migratory agents, agents affecting extracellular matrix production and organization, antineoplastic agents, anti-

mitotic agents, anesthetic agents, anti-coagulants, vascular cell growth promoters, vascular cell growth inhibitors, cholesterol-lowering agents, vasodilating agents, and agents that interfere with endogenous vasoactive mechanisms.

8. The implantable or insertable medical device of claim 1, wherein said silicone copolymer has an elongation at break of at least 25% at ambient temperature.
9. The implantable or insertable medical device of claim 1, wherein said non-siloxane units are elevated T_g non-siloxane units corresponding to monomers selected from vinyl monomers, aromatic monomers, methacrylic monomers, acrylic monomers and alkene monomers.
10. The implantable or insertable medical device of claim 1, wherein said copolymer is a block copolymer comprising (a) a block of said siloxane units and (b) a block of elevated T_g non-siloxane units.
11. The implantable or insertable medical device of claim 10, wherein said block of said elevated T_g non-siloxane units is selected from poly(vinyl monomer) blocks, poly(aromatic monomer) blocks, poly(methacrylic monomer) blocks, poly(acrylic monomer) blocks and poly(alkene monomer) blocks.
12. The implantable or insertable medical device of claim 10, wherein said block of said elevated T_g non-siloxane units is selected from substituted and unsubstituted polystyrene blocks.
13. The implantable or insertable medical device of claim 10, wherein said block of said elevated T_g non-siloxane units is selected from substituted and unsubstituted poly(alkyl methacrylate) blocks.
14. The implantable or insertable medical device of claim 10, wherein said block of said elevated T_g non-siloxane units is selected from poly(styrene) blocks, poly(methyl methacrylate) blocks, poly(ethyl methacrylate) blocks, poly(isopropyl methacrylate)

blocks, poly(isobutyl methacrylate) blocks, poly(t-butyl methacrylate) blocks and poly(cyclohexyl methacrylate) blocks.

15. The implantable or insertable medical device of claim 10, wherein said block copolymer comprises (a) a first glass transition temperature that is greater than ambient temperature and (b) a second glass transition temperature that is less than ambient temperature.
16. The implantable or insertable medical device of claim 15, wherein said first glass transition temperature that is greater than 75 °C and said second glass transition temperature that is less than 0°C.
17. The implantable or insertable medical device of claim 1, wherein said non-siloxane units are low T_g non-siloxane units corresponding to monomers selected from acrylic monomers, methacrylic monomers, vinyl ether monomers, cyclic ether monomers, ester monomers, unsaturated hydrocarbon monomers, and halogenated unsaturated hydrocarbon monomers.
18. The implantable or insertable medical device of claim 1, wherein said polymeric release region further comprises a supplemental polymer.
19. The implantable or insertable medical device of claim 10, wherein said block copolymer comprises at least two different types of said elevated T_g non-siloxane units.
20. The implantable or insertable medical device of claim 1, wherein said medical device is sterilized using a quantity of radiation effective to kill pathogens.
21. The implantable or insertable medical device of claim 1, wherein said silicone copolymer comprises first and second glass transition temperatures, and wherein said first glass transition temperature is below ambient temperature and wherein said second glass transition temperature is above ambient temperature.

22. The implantable or insertable medical device of claim 10, wherein said block of said siloxane units corresponds to a rubbery phase within said release region at ambient temperatures, and wherein said block of said elevated T_g non-siloxane units corresponds to a hard phase within said release layer at ambient temperatures.
23. The implantable or insertable medical device of claim 10, wherein said block copolymer is selected from a diblock copolymer, a triblock copolymer and a graft copolymer.
24. A method of forming the implantable or insertable medical device of claim 1, comprising: (a) providing a solution comprising (i) a solvent system and (ii) said silicone copolymer; and (b) forming said release region from said solution by removing said solvent system from said solution.
25. The method of claim 24, wherein said solution further comprises a therapeutic agent in dissolved or dispersed form.
26. The method of claim 24, wherein said solution is applied over a therapeutic-agent-containing region that comprises said therapeutic agent.
27. The method of claim 24, wherein said release region is formed by a technique comprising a spraying process.

INTERNATIONAL SEARCH REPORT

International Application No
'US2004/024586

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/34 A61L27/18 A61L29/08 A61L29/06 A61L31/06
A61L31/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/000380 A (SCIMED LIFE SYSTEMS INC) 31 December 2003 (2003-12-31) page 13, line 9 - line 10 '0048!-'0050!	1-27
X	US 4 677 169 A (CRIVELLO JAMES V) 30 June 1987 (1987-06-30) abstract column 5, line 30 - line 36	1-27
X	US 5 200 436 A (KUMAR RAMESH C ET AL) 6 April 1993 (1993-04-06) abstract column 4, line 44 - line 63	1-27
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

19 November 2004

Date of mailing of the international search report

09/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Schnack, A

INTERNATIONAL SEARCH REPORT

International Application No

/US2004/024586

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 512 650 A (LEIR CHARLES M ET AL) 30 April 1996 (1996-04-30) column 1, line 36 - line 44 abstract column 2, line 28 - line 43 -----	1-27
Y	GB 1 580 128 A (BAXTER TRAVENOL LAB) 26 November 1980 (1980-11-26) page 2, line 43 - page 3, line 2 claims 1-24 -----	1-27
X	US 4 254 248 A (FRIENDS GARY D ET AL) 3 March 1981 (1981-03-03) column 4, line 28 - line 32 claims 8,12,15,17,20-23,29 -----	1-27
Y	US 5 772 640 A (MODAK SHANTA ET AL) 30 June 1998 (1998-06-30) abstract claims 1-31 -----	1-27
Y	TANG, LIPING ET AL: "Anti-inflammatory properties of triblock siloxane copolymer-blended materials" BIOMATERIALS , 20(15), 1365-1370 CODEN: BIMADU; ISSN: 0142-9612, 1999, XP002306490 abstract page 1368 - page 1369 -----	1-27
X	WO 02/47731 A (SCIMED LIFE SYSTEMS INC) 20 June 2002 (2002-06-20) page 27, line 18 - line 20 -----	1-27

INTERNATIONAL SEARCH REPORT

International Application No

/US2004/024586

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004000380	A	31-12-2003	US 2003235602 A1 WO 2004000380 A1	25-12-2003 31-12-2003
US 4677169	A	30-06-1987	US 4584356 A DE 3707399 A1 FR 2595707 A1 GB 2188056 A ,B JP 62270611 A CA 1232386 A1 JP 1916508 C JP 6043472 B JP 61113608 A	22-04-1986 24-09-1987 18-09-1987 23-09-1987 25-11-1987 02-02-1988 23-03-1995 08-06-1994 31-05-1986
US 5200436	A	06-04-1993	US 5057619 A EP 0413550 A2 JP 3097735 A	15-10-1991 20-02-1991 23-04-1991
US 5512650	A	30-04-1996	US 5214119 A CA 2166321 A1 DE 69415176 D1 DE 69415176 T2 EP 0739372 A1 JP 9501704 T WO 9503354 A1 US 5461134 A US 5290615 A AR 244729 A1 AU 591989 B2 AU 7447487 A BR 8703101 A CA 1339226 C DE 3752135 D1 DE 3752135 T2 EP 0250248 A2 EP 0737700 A2 ES 2110391 T3 HK 1011036 A1 JP 2901236 B2 JP 10310628 A JP 3075470 B2 JP 10279915 A JP 2799381 B2 JP 8231726 A JP 3024678 B2 JP 10060386 A JP 2784761 B2 JP 63003029 A KR 9609692 B1 KR 9609691 B1 TR 24305 A ZA 8704414 A	25-05-1993 02-02-1995 21-01-1999 29-04-1999 30-10-1996 18-02-1997 02-02-1995 24-10-1995 01-03-1994 30-11-1993 21-12-1989 24-12-1987 08-03-1988 05-08-1997 11-12-1997 16-04-1998 23-12-1987 16-10-1996 16-02-1998 22-09-2000 07-06-1999 24-11-1998 14-08-2000 20-10-1998 17-09-1998 10-09-1996 21-03-2000 03-03-1998 06-08-1998 08-01-1988 23-07-1996 23-07-1996 01-08-1991 22-02-1989
GB 1580128	A	26-11-1980	US 3994988 A CA 1055641 A1 DE 2640241 A1	30-11-1976 29-05-1979 20-10-1977
US 4254248	A	03-03-1981	AU 521284 B2 CA 1128244 A1	25-03-1982 20-07-1982

INTERNATIONAL SEARCH REPORT

International Application No

.../US2004/024586

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4254248	A	DE 3034554 A1	02-04-1981
		ES 8106009 A1	16-09-1981
		FR 2465235 A1	20-03-1981
		GB 2058809 A , B	15-04-1981
		HK 36784 A	04-05-1984
		IE 50233 B1	05-03-1986
		IT 1129251 B	04-06-1986
		JP 56051714 A	09-05-1981
		SE 443667 B	03-03-1986
		SE 8006378 A	14-03-1981
US 5772640	A	30-06-1998	
		AT 245039 T	15-08-2003
		AU 730158 B2	01-03-2001
		AU 1523597 A	01-08-1997
		CA 2241461 A1	17-07-1997
		DE 69629128 D1	21-08-2003
		DE 69629128 T2	03-06-2004
		EP 1273313 A2	08-01-2003
		EP 0874655 A1	04-11-1998
		JP 2000507842 T	27-06-2000
		US 6083208 A	04-07-2000
		WO 9725085 A1	17-07-1997
		US 6106505 A	22-08-2000
		US 6626873 B1	30-09-2003
		US 2004039349 A1	26-02-2004
		US 2001024661 A1	27-09-2001
WO 0247731	A	20-06-2002	
		US 2002107330 A1	08-08-2002
		AU 3085102 A	24-06-2002
		CA 2447900 A1	20-06-2002
		EP 1341565 A2	10-09-2003
		WO 0247731 A2	20-06-2002
		US 2003171496 A1	11-09-2003